滋补肺肾方治疗老年慢性便秘临床观察  

Clinical observation on treating senile constipation with the Zibu Feishen prescription

作　　者：朱欢欢[1] 吕国强[1] 欧强 

机构地区：[1]无锡市第三人民医院,江苏无锡214037

出　　处：《中医临床研究》2018年第31期101-102,共2页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察滋补肺肾方对于老年慢性便秘的临床效果。方法:将100例老年慢性便秘患者分为试验组与对照组,分别给予滋补肺肾方与莫沙比利口服治疗。观察两组患者临床疗效、安全性及治疗前后症状改善情况的差异。结果:试验组总有效率比对照组高,差异显著(P <0.05);治疗后,两组患者布里斯托大便分类法(BSFS)评分、便秘患者生活质量量表(PACQOL)评分均升高,便秘患者症状自评量表(PAC-SYM)评分降低,且试验组BSFS评分、PAC-QOL评分比对照组高,PACSYM评分比对照组低,差异均有统计学意义(P <0.05);两组患者不良反应发生率比较无显著性差异(P> 0.05)。结论:滋补肺肾方与莫沙必利对患者症状、生活质量均有积极作用,且安全性良好,但滋补肺肾方改善效果更为理想,临床应用价值更高。Objective： To observe clinical efects of the Zibu Feishen prescription （ 滋补肺肾方 ） on senile constipation. Methods： 100 patients with senile constipation were randomly divided into the experimental group and the control group, 50 cases in each. The control group was treated with mosapride. The experimental group was treated with the Zibu Feishen prescription. Results： The total efective rate in the experimental group was higher than the control group （P〈0.05）. After treatment, BSFS scores and PAC-QOL scores in two groups were elevated, PAC-SYM scores were decreased. BSFS scores and PAC-QOL scores in the experimental group were higher than the control group. PAC-QOL scores in the experimental group was lower than the control group. There was no signifcant diference in adverse efects rate in two groups. Conclusion： The Zibu Feishen prescription and mosapride on the symptom, life quality of patients had positive efects, and the Zibu Feishen prescription is more efective, safer and worthy of promotion.

关 键 词：滋补肺肾方 老年慢性便秘 

分 类 号：R256.35[医药卫生—中医内科学]